Who May Be Considered for a Bone Marrow Transplant: Disease Stage, Age and Organ Fitness

The folder on the desk is thicker than the one from last month. It holds a bone marrow biopsy report, a stack of blood counts and a single new phrase circled in pen: possible transplant candidate. For the person sitting across from the hematologist, that phrase lands as both hope and a question they had not planned to ask themselves at breakfast.

The question of who can have a bone marrow transplant rarely has a yes-or-no answer on the first visit. Transplant teams weigh three things at once: what the disease is doing right now, how the body is likely to cope with weeks of intensive treatment, and whether a suitable source of healthy stem cells exists. Each of those is a moving target.

This explainer walks through how those judgments are actually made, where age fits in, what organ testing looks for, and why a first answer of “not yet” is often not the same as “no.”

Who can have a bone marrow transplant? The honest short answer

Transplant teams tend to think in three overlapping circles rather than a single checklist. The first circle is the disease: is this a condition where replacing the bone marrow offers a real advantage over other treatments? The second is timing: is the disease in a state where a transplant is likely to hold? The third is the person: can the heart, lungs, liver, kidneys and immune system carry them through conditioning chemotherapy, a stretch of very low blood counts and months of recovery?

Someone sitting inside all three circles is a strong candidate. Someone outside one of them is usually not turned away outright. Instead the team asks what would move them inside. That might mean another cycle of treatment to reach remission, a course of antibiotics for a lingering infection, a cardiology review or a longer donor search.

A fourth consideration applies only when the cells will come from someone else: a donor whose tissue type is compatible must be identified, whether a sibling, an unrelated volunteer from a registry, a half-matched family member or stored umbilical cord blood. The Mayo Clinic describes this matching process as one of the main practical determinants of whether and when a transplant can go ahead.

What people often find surprising is how individualized the evaluation is. Two patients with the same diagnosis, the same age and similar scans can receive different recommendations because their organ reserve, disease genetics or social support differ. The evaluation is less an exam you pass or fail and more a structured conversation in which the team lays out expected benefit, expected risk and the alternatives. According to the NHS, that discussion usually involves the patient, the transplant physician, nursing staff and often a social worker, because the demands of a transplant extend well beyond the hospital.

What actually happens during a bone marrow transplant

Bone marrow is the spongy tissue inside larger bones where blood cells are made. Blood-forming stem cells are the immature cells in that marrow that can become red cells, white cells and platelets. A bone marrow transplant, now more often called a hematopoietic stem cell transplant, replaces damaged or diseased marrow with healthy stem cells so the body can rebuild its blood and immune system.

The procedure unfolds in stages. First comes conditioning: high-dose chemotherapy, sometimes with radiation, given over several days to destroy diseased cells and, when donor cells are used, to suppress the recipient’s immune system so it does not reject the graft. Cleveland Clinic notes that conditioning intensity is chosen to match the disease and the patient’s fitness, which is why organ testing matters so much beforehand.

The transplant itself is not surgery. The stem cells arrive in a bag and flow into a central venous line, a soft tube placed in a large vein near the heart, much like a blood transfusion. Most patients are awake. The cells travel through the bloodstream and settle in the marrow spaces on their own.

Then comes the wait for engraftment, the point at which the new cells begin producing blood cells in measurable numbers. MedlinePlus describes this window as typically running between about 10 and 28 days after infusion. During that stretch, blood counts are at their lowest, infection risk is at its highest and patients rely on transfusions, antimicrobial medicines and close nursing care.

Stem cells are collected either from the donor’s circulating blood after several days of a growth-factor injection that coaxes cells out of the marrow, or, less commonly today, directly from the back of the pelvic bone under anesthesia. Johns Hopkins notes that blood collection, called apheresis, is now the more common route for adult donors.

Autologous vs allogeneic: why the transplant type changes who qualifies

Two broad transplant types exist, and eligibility rules differ between them more than most people expect. An autologous transplant uses the patient’s own stem cells, collected earlier and frozen, then returned after high-dose chemotherapy. An allogeneic transplant uses cells from another person. The Mayo Clinic frames the choice as depending on the disease: autologous transplants are used when the goal is to allow chemotherapy doses that would otherwise be too damaging to the marrow, while allogeneic transplants are used when the marrow itself is the problem or when a new immune system is needed to fight residual disease.

Factor	Autologous (own cells)	Allogeneic (donor cells)
Typical conditions	Multiple myeloma, some lymphomas	Acute leukemias, myelodysplastic syndromes, aplastic anemia, inherited blood disorders
Donor needed	No	Yes; matched sibling, unrelated donor, half-matched relative or cord blood
Graft-versus-host disease risk	None	Present; a major source of complications
Immune effect against disease	None from the graft itself	Yes; donor immune cells can target residual disease
Usual fitness threshold	Somewhat lower because no rejection or GVHD	Higher; conditioning and immune complications place more strain on organs
Common concern in workup	Whether the disease has contaminated collected cells	Whether a suitable donor can be found in time

Because autologous transplants carry no risk of rejection or graft-versus-host disease, teams often accept somewhat older or less fit candidates for them than for allogeneic procedures. Conversely, allogeneic transplants demand more from the body, and the workup is correspondingly stricter. Knowing which type is being proposed clarifies almost every other question about eligibility.

Which diseases and disease stages lead to a transplant referral

The conditions that most often prompt a transplant discussion fall into three families. The first is blood cancers: acute myeloid leukemia, acute lymphoblastic leukemia, certain lymphomas and multiple myeloma. The second is bone marrow failure, where the marrow stops producing enough cells, as in aplastic anemia or myelodysplastic syndromes, a group of disorders in which marrow cells are abnormal and prone to becoming leukemia. The third is inherited disorders of blood or immunity, including sickle cell disease, thalassemia and severe combined immunodeficiency, which are more often transplanted in childhood. Cleveland Clinic and the Mayo Clinic both list these categories in their patient guidance.

Within each family, the referral depends on where the disease sits on its own trajectory. For acute leukemia, genetic features of the leukemia cells found at diagnosis often decide whether a transplant is recommended in the first remission or held back as an option if the disease returns. For lymphoma, transplant is more commonly reserved for disease that has relapsed after initial treatment but still shrinks with chemotherapy. For myeloma, an autologous transplant is frequently built into the initial treatment plan rather than saved for later.

Aplastic anemia is a distinctive case. Here the marrow is empty rather than cancerous, and younger patients with a matched sibling are often offered transplant early, while others may start with immune-suppressing therapy first. In sickle cell disease, transplant is generally considered when the person has had serious complications such as stroke or repeated acute chest episodes, since the risks of the procedure must be balanced against a disease that can now be managed in other ways for many years.

The through-line is that a diagnosis alone rarely settles the question. The stage, the response to prior treatment and the biology of the disease carry as much weight as its name.

Does disease stage matter more than the diagnosis itself?

In many transplant decisions, yes. Remission is the term for a state in which tests no longer detect the disease, or detect only very small amounts. A transplant performed while disease is in remission gives the new marrow or the returned cells a clean field to work in. A transplant performed while disease is active and growing is asking the procedure to do two jobs at once, and that is where outcomes are generally poorer according to the guidance summarized by the Mayo Clinic and Johns Hopkins.

Increasingly, teams also look for what is called measurable residual disease, tiny quantities of cancer cells detectable only with sensitive laboratory methods even when standard tests appear normal. For some leukemias, the presence or absence of residual disease before transplant informs how the team thinks about timing and about treatments given afterward.

Another concept that shapes candidacy is chemo-sensitivity. A lymphoma that shrinks meaningfully when treated again after relapse is behaving differently from one that ignores the same drugs. Autologous transplant is generally offered to the former group, because the high-dose chemotherapy at the heart of that procedure relies on the disease still responding to chemotherapy.

Stage also interacts with the type of transplant. Someone with a high-risk leukemia in first remission may be steered toward an allogeneic transplant precisely because the donor immune system offers an additional line of attack. Someone with a lower-risk form of the same disease may be advised to continue conventional treatment and keep transplant in reserve.

None of this is static. A person told they are not a candidate because their disease is not controlled may become one after further treatment. Transplant physicians often describe their role as watching the disease’s response closely and identifying the moment when the balance of benefit and risk tips in favor of proceeding.

Is there a bone marrow transplant age limit?

There is no single, universal age cutoff, and this is one of the areas where practice has shifted most. Earlier generations of transplant relied on very intensive conditioning that few older bodies could tolerate, so programs set firm upper age limits. The development of reduced-intensity conditioning, a gentler chemotherapy regimen that suppresses the immune system enough to allow donor cells to take hold without fully destroying the recipient’s marrow, changed that calculus. The Mayo Clinic notes that this approach has made allogeneic transplant an option for some older adults and for people with other health conditions who would not have qualified before.

What teams assess instead is sometimes called biological age. A person in their late sixties who walks daily, has normal kidney and heart function and lives independently may be a better candidate than someone two decades younger with poorly controlled diabetes, heart failure and limited mobility. Many programs use a structured geriatric assessment for older candidates that looks at physical function, cognition, nutrition, mood and social support, because each of these predicts how well someone will weather the months after transplant.

Age has not become irrelevant. Older adults are more likely to carry accumulated organ damage, to take multiple medicines that interact with transplant drugs and to recover more slowly from infections. For autologous transplant, where rejection and graft-versus-host disease are not concerns, age thresholds tend to be more relaxed than for allogeneic procedures.

For children, the question is reversed: very young age is generally not a barrier, and pediatric transplant programs routinely treat infants for inherited immune and metabolic disorders. Their evaluation focuses on growth, nutrition, organ maturity and the family’s capacity to manage a demanding recovery, according to Johns Hopkins pediatric guidance.

The practical takeaway is that an older adult should not assume they are ineligible before being evaluated, and a younger adult should not assume they automatically qualify.

Organ fitness: what the pre-transplant workup actually checks

The pre-transplant evaluation is thorough because conditioning chemotherapy and the weeks that follow put every major organ under stress. Cleveland Clinic describes it as a series of tests spread over days to weeks, and most programs follow a similar pattern.

The heart is assessed with an echocardiogram, an ultrasound that measures how effectively the heart pumps, usually expressed as ejection fraction, the share of blood the main chamber pushes out with each beat. Some chemotherapy drugs used in conditioning can weaken heart muscle, so a heart already working near its limit is a concern.

Lungs are tested with pulmonary function tests, breathing measurements that include diffusing capacity, an estimate of how well oxygen crosses from the air sacs into the blood. Lung infections and a form of lung inflammation linked to transplant are common complications, so reserve matters.

Blood tests measure liver enzymes and kidney filtration. The liver processes many transplant medicines and is vulnerable to a condition in which small vessels within it become blocked after intensive conditioning. The kidneys clear drugs and must cope with antibiotics and immune-suppressing medicines that can be hard on them.

Infection screening looks for viruses such as hepatitis, HIV and cytomegalovirus, which can reactivate when immunity is low. A dental review often precedes transplant because a hidden tooth abscess can become a serious infection during the low-count period.

Teams also record performance status, a simple scale rating how much of daily life a person can manage unaided, and frequently calculate a comorbidity index that adds up existing conditions to estimate risk. A psychosocial assessment covers caregiver availability, housing near the center during early recovery and the ability to follow a complex medication schedule. None of these tests exists to exclude people; they exist to tailor conditioning intensity, anticipate complications and decide what needs optimizing first.

What disqualifies you from a bone marrow transplant?

Few findings are absolute barriers, but several situations lead teams to advise against transplant, at least for now. The most common is active, uncontrolled disease that has not responded to available treatment. Transplanting into progressing disease rarely holds, and the risks of the procedure are borne without its likely benefit.

Severe organ dysfunction is the second major reason. Marked heart failure, advanced lung disease requiring oxygen, cirrhosis or kidney failure needing dialysis can each make conditioning unsafe. Where dysfunction is moderate rather than severe, teams may still proceed using reduced-intensity approaches, so a single abnormal result is not necessarily decisive.

An active, uncontrolled infection almost always pauses the process, because conditioning removes the body’s defenses just when it needs them. The same applies to a second active cancer that has not been treated, since its behavior during a period of profound immune suppression is unpredictable.

Poor performance status, meaning someone is spending most of the day in bed or needs help with basic self-care unrelated to a temporary setback, predicts difficulty recovering and is weighed heavily. The NHS guidance on stem cell transplant emphasizes that patients need to be well enough to cope with the intensive treatment.

Practical circumstances count too. The months after an allogeneic transplant require dozens of clinic visits, strict medication adherence and, in most programs, a caregiver who can be present around the clock in the early weeks. When these supports are absent, teams work with social workers to find solutions before proceeding rather than simply declining.

Uncontrolled mental health conditions or ongoing substance use that would make adherence unsafe are addressed in the same spirit: as problems to treat and revisit, with care and without judgment. Most of what people call disqualification is better described as a set of conditions that need to be met first.

Who is usually asked to wait, and why waiting is not the same as no

A large share of people evaluated for transplant hear some version of “not yet.” Understanding the reasons behind that phrase makes it far easier to live with.

The most frequent reason is that the disease needs more treatment to reach remission. This is sometimes called bridging therapy: additional chemotherapy, a targeted drug or immunotherapy given specifically to bring the disease under control so the transplant has the best chance of holding. The wait can feel like a delay but is, in effect, the first step of the transplant itself.

Infections are another common cause. A fungal lung infection, a persistent viral illness or an infected tooth all need to be treated before conditioning. Because conditioning wipes out white cells, anything smoldering beforehand can flare dangerously afterward.

Organ optimization is a third. A cardiologist may adjust heart medicines and repeat an echocardiogram in a few weeks. A person who smokes will be strongly encouraged to stop, since lung complications and delayed healing are well-documented in smokers. Someone with poorly controlled diabetes may work with an endocrinologist first, because high blood sugar impairs infection defenses during the low-count period.

Donor availability also imposes waits. Finding and confirming an unrelated donor through international registries, then scheduling collection, can take weeks to months according to the Mayo Clinic. Teams sometimes pursue a half-matched family donor or cord blood in parallel to keep the timeline moving.

Finally, some people are asked to wait because their disease is behaving well without transplant and the team judges that the risks of proceeding now outweigh the benefits. In that case the plan is active monitoring, with transplant held as an option if circumstances change. Asking the team to name the specific conditions that would turn a wait into a go is one of the most useful things a patient can do.

Finding a donor: matching, and why registries limit older donors

Allogeneic transplant depends on human leukocyte antigen, or HLA, matching. HLA markers are proteins on the surface of cells that the immune system uses to tell self from non-self. The closer the match between donor and recipient, the lower the risk that donor immune cells attack the recipient’s tissues, a complication called graft-versus-host disease, and the lower the risk that the recipient’s body rejects the graft.

Full siblings are the first place teams look. Because HLA genes are inherited as a set from each parent, the NHS notes that each full sibling has roughly a one-in-four chance of being a full match. When no sibling matches, the search widens to volunteer registries. Half-matched, or haploidentical, transplants from a parent, child or sibling have become far more feasible thanks to newer approaches to preventing graft-versus-host disease, and stored umbilical cord blood offers another source, particularly for children.

People frequently ask why registries stop accepting new donors past a certain age. It is a registry policy, not a medical prohibition. Two lines of reasoning drive it. First, analyses of transplant outcomes have generally found that recipients tend to do better with cells from younger donors, so registries prioritize recruiting younger adults. Second, donation involves either several days of growth-factor injections followed by apheresis or a procedure under anesthesia to draw marrow from the pelvic bone, and the small risks of both rise with age. Registries set an upper enrollment age and usually retire existing volunteers at a slightly older threshold to balance donor safety with recipient benefit.

A parent or sibling past registry age is not excluded from donating to their own family member; that decision is made by the transplant team on an individual basis. Cleveland Clinic’s donor guidance emphasizes that anyone considering donation receives a full medical screening first, whatever their age.

What the following days and weeks usually look like

Once a person is cleared, the timeline becomes more predictable, though every course has its own texture. A central line is placed. Conditioning begins, typically lasting several days according to MedlinePlus, with anti-nausea medicines given alongside. The infusion day is counted as day zero, and everything afterward is described in days from that point.

The first two to three weeks after infusion are the hardest for most people. White cells fall to near zero, the lining of the mouth and gut often becomes sore, appetite disappears and fatigue can be profound. Transfusions of red cells and platelets are routine. Preventive antimicrobials are standard, and any fever is treated urgently. Patients are usually in a specialized unit with air filtration and visitor restrictions.

Engraftment, the return of measurable white cells, typically arrives somewhere between roughly 10 and 28 days after infusion per MedlinePlus. Mouth pain eases and energy begins, slowly, to return. For allogeneic recipients, this is also when the earliest signs of acute graft-versus-host disease, often a skin rash, diarrhea or changes in liver tests, may appear and prompt adjustment of immune-suppressing medicines by the team.

Discharge follows once counts are stable, eating is possible and no active infection is present. The Mayo Clinic describes the hospital stay as commonly lasting several weeks, and many programs ask allogeneic recipients to remain close to the center with a caregiver for approximately the first hundred days, a period of frequent clinic visits and blood tests.

Full immune recovery is measured in months to years. The Mayo Clinic notes that it can take a year or longer for the immune system to recover, which is why childhood vaccinations are typically repeated on a schedule set by the team. Fatigue frequently lingers well past the point where blood counts look normal, and a gradual return to work and activity is the norm rather than the exception.

What are the downsides of a bone marrow transplant?

Any honest discussion of candidacy has to sit with the risks, because the decision is ultimately a trade between the danger of the disease and the danger of the treatment. The Mayo Clinic and MedlinePlus both list the principal complications, and they cluster into a few groups.

Infection is the most immediate. During the weeks before engraftment, the body has almost no white cells, and bacterial, fungal and viral infections can escalate quickly. Even after counts recover, the new immune system remains immature for many months, and viruses that were dormant, such as cytomegalovirus, can reactivate.

Graft-versus-host disease applies to allogeneic transplant only. In its acute form it affects the skin, gut and liver in the early months. In its chronic form it can involve the eyes, mouth, skin, joints and lungs for years and requires long-term immune-suppressing treatment. It is both a major source of complications and, paradoxically, linked to the beneficial effect donor cells have against residual disease.

Organ injury from conditioning includes damage to the lungs, liver and heart, and a specific liver complication in which small blood vessels become obstructed. Graft failure, where the new cells do not engraft or later stop working, is uncommon but serious.

Longer-term effects deserve equal attention. High-dose chemotherapy and radiation commonly cause infertility, which is why fertility preservation is discussed before conditioning whenever time allows. Secondary cancers can develop years later. Cataracts, thyroid problems, bone thinning and persistent fatigue are recognized late effects.

There are also demands that do not appear in a complications list: weeks of hospitalization, months away from work, a caregiver whose life is reorganized, and the emotional weight of a treatment whose result is not known for a long time. These are legitimate factors in a decision, and good teams address them directly rather than treating them as afterthoughts.

Alternatives when a transplant is not the right fit

Being told a transplant is not recommended, or not recommended yet, does not mean treatment stops. For most of the conditions involved, other paths exist, and for some patients they are the better path even when transplant is technically possible.

For blood cancers, the landscape has broadened considerably. Targeted therapies, medicines designed to block a specific molecular abnormality driving the cancer, now exist for several leukemia and lymphoma subtypes. Immunotherapies, which harness the patient’s own immune system, include antibody-based drugs and cellular therapies in which a patient’s T cells are engineered to recognize cancer and returned to them. These are approved for certain relapsed lymphomas and leukemias and are sometimes used instead of, before or after a transplant depending on the situation. Whether any of these is appropriate is a decision for the treating hematologist based on the specific disease.

For myeloma, continuous drug-based therapy without transplant is a recognized approach, particularly for people who are frailer or who prefer to avoid intensive treatment. For myelodysplastic syndromes, supportive care with transfusions and growth factors, or lower-intensity chemotherapy, can control the condition for extended periods.

In aplastic anemia, immune-suppressing therapy is a standard first-line alternative to transplant. In sickle cell disease and thalassemia, disease-modifying medicines, regular transfusion programs and, more recently, gene-based therapies that modify the patient’s own cells are available options that the care team may discuss.

Clinical trials are a legitimate route for anyone whose standard options are limited, and asking about them is reasonable at any stage. Palliative and supportive care, which focuses on symptom control and quality of life, can run alongside any of these approaches and is not a signal that active treatment has ended. The NHS and Mayo Clinic both encourage patients to ask explicitly how each alternative compares with transplant in their own case.

What people often get wrong about bone marrow transplant eligibility criteria

Misconceptions cluster around a handful of themes, and several of them cause people to rule themselves out, or in, prematurely.

“I’m too old.” Chronological age alone rarely decides candidacy today. Reduced-intensity conditioning and structured fitness assessments have widened the door for older adults, as the Mayo Clinic notes. The evaluation is the only way to know.

“Transplant is a last resort.” For some diseases, particularly high-risk acute leukemia and myeloma, transplant is recommended in the first remission rather than after everything else has failed. Waiting until the disease is uncontrolled often makes a person less eligible, not more.

“I need a family donor.” Unrelated registry donors, half-matched relatives and cord blood mean that lack of a matched sibling is no longer the barrier it once was, according to Cleveland Clinic.

“It’s an operation.” The infusion is a transfusion through a line, not surgery. The intensity lies in the conditioning beforehand and the recovery afterward.

“There’s a single life expectancy number.” People ask what the average life expectancy after transplant is, and the honest answer is that no single figure applies. Outcomes reported in transplant registries vary widely by disease, remission status, transplant type, donor match, age and comorbidity. A transplant physician can discuss what published data suggest for a specific situation, and that individualized conversation is far more meaningful than any headline average.

“Donating is dangerous major surgery.” Most adult donations now happen through apheresis after growth-factor injections, an outpatient process, per Johns Hopkins. Marrow harvest from the pelvis, when used, is done under anesthesia and donors typically return to normal activity within days to a couple of weeks, as MedlinePlus describes.

“Once I’m told no, that’s final.” Most declines are conditional. Treating an infection, reaching remission or improving heart function can reopen the question.

Questions to ask your care team about stem cell transplant requirements

The evaluation conversation goes better when a patient arrives with questions written down. These are the ones transplant nurses and physicians say they most wish people would ask.

• Which type of transplant are you proposing for me, autologous or allogeneic, and why that one?
• What is it about my disease right now, its stage, genetics or response to treatment, that makes transplant a reasonable option?
• Is there a specific remission status or test result I need to reach before we proceed?
• Which of my organ test results are you most focused on, and what would change if they were different?
• What conditioning intensity are you planning, and how does my age or health influence that choice?
• If I need a donor, what sources are you searching, and how long might that take?
• What are the most likely complications for someone in my situation, and how do you manage them?
• What alternatives to transplant exist for my disease, and how do they compare in your judgment?
• What does the first three months after discharge require of me and of my caregiver?
• Should I see a fertility specialist before conditioning begins?
• What late effects should I know about years from now, and how will they be monitored?
• Are there clinical trials relevant to my situation?
• Who do I call, day or night, if something worries me during evaluation or after transplant?

It also helps to ask how the team will keep in touch with the referring hematologist and primary care clinician, and whether a social worker or psychologist is part of the transplant service. Bringing a family member or friend to take notes is standard advice from the NHS and Mayo Clinic, because the volume of information in a single visit is considerable. There is no wrong question, and a good team will welcome the ones that are hardest to ask.

When to call your doctor

Red-flag symptoms matter at every stage of the transplant journey, including during the evaluation period when the underlying disease may still be active and blood counts may already be low.

Fever is the single most important sign. The Mayo Clinic advises transplant patients to contact their team promptly for a temperature of 100.4°F (38°C) or higher, and most programs treat any fever during the low-count period as an emergency, because infection can progress within hours when white cells are scarce. Chills, shaking or feeling suddenly unwell warrant the same urgency even without a documented fever.

Other signs that call for immediate contact with the care team or emergency services include:

• Bleeding that does not stop, blood in urine or stool, or a rapidly spreading rash of small red or purple spots, which can indicate very low platelets.
• New or worsening shortness of breath, chest pain or a racing heartbeat.
• Redness, swelling, pain or discharge at a central line site, or a line that will not flush.
• Confusion, severe headache, a seizure, or sudden weakness or numbness.
• Persistent vomiting or diarrhea, especially with a new rash after an allogeneic transplant, since these can signal graft-versus-host disease.
• Yellowing of the skin or eyes, dark urine or marked abdominal swelling.
• Inability to keep down prescribed medicines, particularly immune-suppressing drugs after an allogeneic transplant.

Caregivers should know these signs as well as the patient does and should have the transplant unit’s contact number available at all times. Transplant programs expect calls, including ones that turn out to be nothing. A question raised early is far easier to manage than a complication caught late, and the team, not the patient, should be the one deciding whether a symptom can wait until morning.

Frequently asked questions

What disqualifies you from a bone marrow transplant?

The most common reasons are active disease that has not responded to treatment, severe heart, lung, liver or kidney dysfunction, an uncontrolled infection, an untreated second cancer, or a performance status so limited that recovery is unlikely. Most of these are conditional rather than permanent: once an infection is treated or remission is reached, the evaluation can be repeated. Practical barriers such as no available caregiver are usually addressed with social work support rather than treated as final.

What is the average life expectancy after a bone marrow transplant?

No single average applies, and any headline figure would be misleading. Outcomes reported in transplant registries vary widely with the underlying disease, whether it was in remission, the transplant type, the closeness of the donor match, the recipient’s age and the presence of other health conditions. A transplant physician can discuss what published data suggest for a specific situation, and that individualized conversation is the only meaningful way to approach this question.

What are the downsides of a bone marrow transplant?

The principal risks are serious infection during the weeks of very low blood counts, graft-versus-host disease after donor transplants, organ injury from conditioning chemotherapy, and graft failure. Longer-term effects include infertility, secondary cancers, cataracts, thyroid problems and prolonged fatigue. Beyond medical complications, the process demands weeks in hospital, months of restricted activity and a caregiver’s sustained involvement. The Mayo Clinic and MedlinePlus describe these risks in their patient guidance.

Why can't people over 60 donate bone marrow?

This is a registry enrollment policy rather than a medical rule. Registries prioritize younger volunteers because outcome analyses have generally found recipients tend to do better with cells from younger donors, and because the small risks of donation, whether apheresis after growth-factor injections or marrow collection under anesthesia, rise with age. An older parent or sibling can still be considered as a donor for their own family member, a decision the transplant team makes individually after screening.

Is there a bone marrow transplant age limit?

Not a fixed one. Programs once set firm upper limits because intensive conditioning was too harsh for older bodies, but reduced-intensity regimens have made allogeneic transplant possible for some older adults, as the Mayo Clinic notes. Teams now weigh biological age through organ testing, performance status and often a geriatric assessment. Autologous transplants generally have more relaxed age thresholds than donor transplants because rejection and graft-versus-host disease are not concerns.

What are the bone marrow transplant eligibility criteria?

Eligibility rests on a disease that benefits from transplant, a disease state that is in remission or responding to treatment, and adequate organ function measured by echocardiogram, pulmonary function tests and blood work for liver and kidneys. Teams also assess performance status, existing health conditions, infection screening and psychosocial support. For allogeneic transplant, a suitably matched donor must be identified. Each program applies these criteria with judgment rather than as a rigid checklist.

What are the stem cell transplant requirements for a donor?

A donor must be an acceptable HLA match, meaning their tissue-type markers are compatible with the recipient’s, and must pass a medical screening covering infections, heart and lung health, and conditions that would make growth-factor injections or anesthesia unsafe. Full siblings have roughly a one-in-four chance of matching according to the NHS. Unrelated registry donors, half-matched relatives and cord blood are alternatives when no sibling matches.

Can you have a bone marrow transplant if the disease is not in remission?

It is sometimes done, but transplant into active, uncontrolled disease is associated with poorer outcomes, so most teams first give additional treatment to reach remission or at least meaningful response. This bridging therapy is effectively the first step of the transplant plan. Whether to proceed without full remission depends on the specific disease, its behavior and the alternatives available, and is a judgment made by the treating team.

How long does the bone marrow transplant process take from start to finish?

The evaluation typically spans days to weeks, a donor search can add weeks to months per the Mayo Clinic, conditioning lasts several days according to MedlinePlus, and the hospital stay commonly runs several weeks. Engraftment usually occurs within roughly 10 to 28 days of infusion. Many programs ask allogeneic recipients to stay near the center for about the first hundred days, and the Mayo Clinic notes immune recovery can take a year or longer.

What happens if I am told I am not a transplant candidate?

Treatment continues along other paths. Depending on the disease, options may include targeted therapies, immunotherapies, continuous drug-based treatment, immune-suppressing therapy, transfusion support or clinical trials, all decided with the treating hematologist. Many declines are conditional, and the team can specify what would need to change for the question to be reopened. Supportive care for symptoms and quality of life runs alongside any of these approaches.

References

• Bone marrow transplant – MedlinePlus Medical Encyclopedia
• Stem cell and bone marrow transplants – NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.